KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Deferred Taxes (2016 - 2017)

Historic Deferred Taxes for Travere Therapeutics (TVTX) over the last 4 years, with Q4 2017 value amounting to $1.4 million.

  • Travere Therapeutics' Deferred Taxes rose 11188.48% to $1.4 million in Q4 2017 from the same period last year, while for Sep 2018 it was $1.4 million, marking a year-over-year increase of 10711.75%. This contributed to the annual value of -$6.4 million for FY2017, which is 7164.73% up from last year.
  • According to the latest figures from Q4 2017, Travere Therapeutics' Deferred Taxes is $1.4 million, which was up 11188.48% from -$2.4 million recorded in Q3 2017.
  • Over the past 5 years, Travere Therapeutics' Deferred Taxes peaked at $28.2 million during Q3 2015, and registered a low of -$40.0 million during Q1 2015.
  • In the last 4 years, Travere Therapeutics' Deferred Taxes had a median value of -$2.9 million in 2014 and averaged -$3.9 million.
  • Within the past 5 years, the most significant YoY rise in Travere Therapeutics' Deferred Taxes was 11188.48% (2017), while the steepest drop was 28578.09% (2017).
  • Over the past 4 years, Travere Therapeutics' Deferred Taxes (Quarter) stood at -$2.5 million in 2014, then plummeted by 53.74% to -$3.8 million in 2015, then plummeted by 208.36% to -$11.7 million in 2016, then soared by 111.88% to $1.4 million in 2017.
  • Its Deferred Taxes was $1.4 million in Q4 2017, compared to -$2.4 million in Q3 2017 and -$3.4 million in Q2 2017.